Ovarian Cancer Clinical Trial
— BE-BALANCEDOfficial title:
Targeted Physical Activity to Improve Mobility and Falls Risk in Women Living With Ovarian Cancer (The BE-BALANCED Study)
This study will explore the feasibility (suitability), efficacy (research-setting outcomes), and participant satisfaction of a virtually-supervised 12-week exercise and diet intervention for women with ovarian cancer. It will include exercise, behavior change strategies, and guidance around healthy eating. Participants will be instructed and supervised virtually in two exercise sessions weekly for 12 weeks by a professional trained to deliver the program. An additional 1 exercise session per week, completed independently, will be added from weeks 4-12 of the program. Finally participants will participate in two separate virtual group nutrition sessions. Assessments will occur at baseline, end-of-intervention, and 6 months post-baseline.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 50 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. 50-75 years of age (women tend to be older at time of diagnosis, with a median age in Canada of 62 years); 2. Completed primary chemotherapy treatment (oral maintenance therapy allowed); 3. Are within one year of completion of primary chemotherapy without known recurrence; 4. Have access to a smartphone, tablet, laptop, or desktop computer with a camera and microphone, and a reliable internet connection; 5. Speak English, to ensure safety in delivery of the physical activity intervention Exclusion Criteria: 1. Do not pass pre-exercise screening for safety and do not subsequently provide written medical clearance from their physician to participate; 2. Do not consent to adhere to safety requirements to participate in a virtual delivery program (i.e., be seen on video for duration of class); 3. Experienced a fall requiring medical attention in the prior 6 months as individuals may be a higher risk for fall in a virtual physical activity program setting and would be more appropriate for referral to falls clinic |
Country | Name | City | State |
---|---|---|---|
Canada | Clinical Exercise Physiology Lab | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | British Columbia Cancer Agency |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Evaluate patient satisfaction | Overall satisfaction; measured on scale 0-7 with higher score meaning higher satisfaction. | Baseline to 12 weeks | |
Primary | Accrual | Assessed by meeting accrual targets (number recruited) | Baseline (0 weeks) | |
Primary | Intervention Adherence | Assessed as number of supervised virtual sessions that a participant attended, out of a total of 24 group exercise sessions, and number of self-directed sessions completed, out of a total of 9 sessions. | Baseline to 12 weeks | |
Primary | Attrition | Assessed as number of drop-outs during the 12-week program. | Baseline to 12 weeks | |
Primary | Fidelity of group belonging | Group Belonging Scale (0-20; higher is better) | Baseline to 12 weeks | |
Secondary | Physical function: Gait speed | Measured by the gait speed portion of The Short Physical Performance Battery. Measured in seconds. | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Physical function: Functional mobility | Measured by 8 foot timed up and go (Seniors Fitness Test). Measured by distance in seconds. | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Physical function: Lower extremity strength and endurance | Measured by 30-second chair stand (Seniors Fitness Test). Measured in repetitions completed. | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Physical function: Upper extremity strength and endurance | Measured by 30-second biceps curl (Seniors Fitness Test). Measured in repetitions completed. | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Physical function: Balance | Measured by Functional Reach Test. Measured in centimeters. | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Cardiovascular Fitness | Measured by the Six Minute Walk test. Measured in meters. | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Height | Measured using stadiometer. Measured in meters | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Weight | Measured using a scale. Measured in kilograms | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Body mass index | Aggregated measure of height and weight, reported in kilograms/meter^2 | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Waist circumference | Measured in centimeters | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Hip circumference | Measured in centimeters | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Health-related quality of life: Physical Health | Measured by 36-item Short Form Health Survey; Norm-based 0-100, higher score represents better health | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Health-related quality of life: Mental Health | Measured by 36-item Short Form Health Survey; Norm-based 0-100, higher score represents better health | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Depression and anxiety | Measured by Hospital Anxiety and Depression Scale; Score range 0-21, higher score is higher depression and anxiety. | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Usual physical activity levels | Measured by Modified Godin Leisure Time Physical Activity questionnaire; Scoring range 0 - no specified maximum. Scoring < 14 units "insufficiently Active" ; 14-23 is "moderately active" and >=24 is "active". | Change from baseline to 12 weeks (end of intervention) | |
Secondary | Falls | Measured by standard falls calendar for the duration of the study as number of falls. | Change from baseline to 12 weeks (end of intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |